Clearside Biomedical, Inc. financial data

Symbol
CLSD on Nasdaq
Industry
Pharmaceutical Preparations
Location
900 North Point Parkway, Suite 200, Alpharetta, GA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 27, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 505 % -17.1%
Debt-to-equity -204 % +65.5%
Return On Equity 111 % -73.5%
Return On Assets -107 % -25.5%
Operating Margin -1.74K % -475%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 77.1M shares +3.24%
Common Stock, Shares, Outstanding 76.6M shares +21.8%
Entity Public Float 92M USD +43.8%
Common Stock, Value, Issued 77K USD +22.2%
Weighted Average Number of Shares Outstanding, Basic 73.8M shares +19.4%
Weighted Average Number of Shares Outstanding, Diluted 73.8M shares +19.4%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 1.66M USD -79.8%
Research and Development Expense 18.6M USD -10.8%
General and Administrative Expense 11.8M USD -0.52%
Operating Income (Loss) -28.9M USD -16.3%
Net Income (Loss) Attributable to Parent -34.4M USD -5.75%
Earnings Per Share, Basic -0.47 USD/shares +11.3%
Earnings Per Share, Diluted -0.47 USD/shares +11.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 20M USD -30.8%
Cash, Cash Equivalents, and Short-term Investments 23.6M USD
Accounts Receivable, after Allowance for Credit Loss, Current 507K USD +8.57%
Other Assets, Current 13K USD -7.14%
Assets, Current 21.3M USD -29.4%
Property, Plant and Equipment, Net 3.23M USD +7.64%
Operating Lease, Right-of-Use Asset 597K USD -31.3%
Other Assets, Noncurrent 30K USD 0%
Assets 25.1M USD -26.1%
Accounts Payable, Current 1.45M USD -34.2%
Employee-related Liabilities, Current 2.16M USD +16%
Accrued Liabilities, Current 2.97M USD -28.8%
Liabilities, Current 4.79M USD -29.6%
Operating Lease, Liability, Noncurrent 328K USD -49.5%
Other Liabilities, Noncurrent 400K USD -16.7%
Liabilities 64M USD +28.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax 5K USD
Retained Earnings (Accumulated Deficit) -355M USD -10.7%
Stockholders' Equity Attributable to Parent -38.9M USD -144%
Liabilities and Equity 25.1M USD -26.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7.85M USD -8.8%
Net Cash Provided by (Used in) Financing Activities 14.3M USD +4220%
Net Cash Provided by (Used in) Investing Activities -57K USD +50.4%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 76.6M shares +21.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6.44M USD
Deferred Tax Assets, Valuation Allowance 92.4M USD +9.93%
Operating Lease, Liability 703K USD -30.6%
Depreciation 28K USD +86.7%
Payments to Acquire Property, Plant, and Equipment 57K USD -50.4%
Property, Plant and Equipment, Gross 4.37M USD +11.6%
Operating Lease, Liability, Current 375K USD +3.02%
Deferred Tax Assets, Operating Loss Carryforwards 56M USD +6.39%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 7.05M USD -6.26%
Additional Paid in Capital 316M USD +3.74%
Preferred Stock, Shares Outstanding 0 shares
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%